Menu
Search
|

Menu

Close
X

Keryx Biopharmaceuticals Inc KERX.OQ (NASDAQ Stock Exchange Capital Market)

3.21 USD
-- (--)
As of Oct 19
chart
Previous Close 3.21
Open --
Volume --
3m Avg Volume 259,433
Today’s High --
Today’s Low --
52 Week High 6.66
52 Week Low 2.79
Shares Outstanding (mil) 120.46
Market Capitalization (mil) 386.67
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.29 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
48
FY17
61
FY16
32
FY15
14
EPS (USD)
FY18
-0.366
FY17
-1.436
FY16
-1.522
FY15
-1.184
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
4.76
6.55
Price to Book (MRQ)
vs sector
--
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
--
14.15
LT Debt to Equity (MRQ)
vs sector
--
11.31
Return on Investment (TTM)
vs sector
-80.19
12.83
Return on Equity (TTM)
vs sector
--
14.95

EXECUTIVE LEADERSHIP

Michael Rogers
Chairman of the Board, Since 2017
Salary: $70,000.00
Bonus: --
Jodie Morrison
Interim Chief Executive Officer, Director, Since 2018
Salary: $41,739.00
Bonus: --
Scott Holmes
Chief Financial Officer, Treasurer, Since 2015
Salary: $373,969.00
Bonus: --
Christine Carberry
Chief Operating Officer, Since 2017
Salary: $357,718.00
Bonus: $14,630.00
John Neylan
Chief Medical Officer, Since 2015
Salary: $428,047.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 Marina Park Dr
BOSTON   MA   02210-1832

Phone: +1617.4663500

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.

SPONSORED STORIES